股市必读：兄弟科技（002562）9月22日主力资金净流出4019.67万元

Group 1 - The core point of the article is that Brother Technology's subsidiary, Zhejiang Brother Pharmaceutical Co., Ltd., has received a drug registration certificate for Iopamidol injection, which is now approved for market sale in China [1][3] - The Iopamidol injection is classified as a Class 4 chemical drug and has been included in the National Medical Insurance Class A directory and the seventh batch of national drug centralized procurement [1][3] - The domestic market size for Iopamidol is projected to be approximately 450 million yuan in 2024, indicating a significant market opportunity for the company [1] Group 2 - On September 22, Brother Technology's stock closed at 7.17 yuan, down 1.92%, with a turnover rate of 13.39% and a trading volume of 939,200 shares, amounting to a transaction value of 675 million yuan [1] - The net outflow of main funds on September 22 was 40.2 million yuan, while retail investors saw a net inflow of 48.0 million yuan [1][3] - The approval of the drug registration certificate is expected to enhance the company's product line in iodine contrast agents and improve its market competitiveness [1]